Find Dexlansoprazole manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FDF DossiersDRUG PRODUCT COMPOSITIONS

130RELATED EXCIPIENT COMPANIES

220EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: (r)-lansoprazole, 138530-94-6, Kapidex, R-(+)-lansoprazole, Dexilant, Dexilant solutab
Molecular Formula
C16H14F3N3O2S
Molecular Weight
369.4  g/mol
InChI Key
MJIHNNLFOKEZEW-RUZDIDTESA-N
FDA UNII
UYE4T5I70X

Dexlansoprazole
The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.
Dexlansoprazole is a Proton Pump Inhibitor. The mechanism of action of dexlansoprazole is as a Proton Pump Inhibitor.
1 2D Structure

Dexlansoprazole

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2.1.2 InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
2.1.3 InChI Key
MJIHNNLFOKEZEW-RUZDIDTESA-N
2.1.4 Canonical SMILES
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
2.1.5 Isomeric SMILES
CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
UYE4T5I70X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole

2. Dexilant

3. Dexlansoprazole Sesquihydrate

4. Lansoprazole, R Isomer

5. Lansoprazole, R-isomer

6. R Lansoprazole

7. R-isomer Lansoprazole

8. R-lansoprazole

9. T 168390

10. T-168390

11. T168390

12. Tak 390

13. Tak 390mr

14. Tak-390

15. Tak-390mr

16. Tak390

17. Tak390mr

2.3.2 Depositor-Supplied Synonyms

1. (r)-lansoprazole

2. 138530-94-6

3. Kapidex

4. R-(+)-lansoprazole

5. Dexilant

6. Dexilant Solutab

7. Tak 390

8. Tak-390

9. Lansoprazole R-form

10. Lansoprazole, (r)-

11. T 168390

12. (r)-(+)-lansoprazole

13. T-168390

14. Uye4t5i70x

15. (r)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole

16. Nsc-758710

17. 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole

18. Tak-390mr

19. 1h-benzimidazole, 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-

20. Dexlansoprazole [usan]

21. Unii-uye4t5i70x

22. Dexlansoprazole (inn/usan)

23. Dexlansoprazole [usan:inn]

24. (+)-lansoprazol

25. 2-[(r)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

26. Dexilant (tn)

27. (+)-2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1h-benzimidazole

28. (+)-2-((r)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1h-benzimidazole

29. 1h-benzimidazole, 2-[(r)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-

30. Schembl44975

31. Dexlansoprazole [inn]

32. Dexlansoprazole [vandf]

33. Gtpl5487

34. Dexlansoprazole [mart.]

35. Chembl1201863

36. Dexlansoprazole [who-dd]

37. Lansoprazole R-form [mi]

38. 2-[(r)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole

39. Chebi:135931

40. Hms3652c14

41. Zinc599734

42. Amy25226

43. Bdbm50247930

44. Dexlansoprazole [orange Book]

45. Hy-13662b

46. Mfcd13196699

47. S4099

48. Akos025290765

49. Ccg-213301

50. Db05351

51. Nsc 758710

52. Pb33188

53. 2-[(r)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1h-benzimidazole

54. Ncgc00386267-03

55. Ac-26449

56. As-18086

57. Sw219466-1

58. D08903

59. Ab01563023_01

60. Ab01563023_02

61. Q5268339

62. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

63. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole

64. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1h-benzimidazole

65. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole

66. (r)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1h-benzimidazole

67. 2-[(r)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1h-1,3-benzodiazole

2.4 Create Date
2006-10-24
3 Chemical and Physical Properties
Molecular Weight 369.4 g/mol
Molecular Formula C16H14F3N3O2S
XLogP32.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass369.07588236 g/mol
Monoisotopic Mass369.07588236 g/mol
Topological Polar Surface Area87.1 Ų
Heavy Atom Count25
Formal Charge0
Complexity480
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameDexilant
PubMed HealthDexlansoprazole (By mouth)
Drug ClassesGastric Acid Secretion Inhibitor
Drug LabelThe active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion...
Active IngredientDexlansoprazole
Dosage FormCapsule, delayed release
RouteOral
Strength60mg; 30mg
Market StatusPrescription
CompanyTakeda Pharms Usa

2 of 4  
Drug NameDexlansoprazole
PubMed HealthDexlansoprazole (By mouth)
Drug ClassesGastric Acid Secretion Inhibitor
Drug LabelThe active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion...
Active IngredientDexlansoprazole
Dosage FormCapsule, extended release
RouteOral
Strength60mg
Market StatusTentative Approval
CompanyPar Pharm

3 of 4  
Drug NameDexilant
PubMed HealthDexlansoprazole (By mouth)
Drug ClassesGastric Acid Secretion Inhibitor
Drug LabelThe active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion...
Active IngredientDexlansoprazole
Dosage FormCapsule, delayed release
RouteOral
Strength60mg; 30mg
Market StatusPrescription
CompanyTakeda Pharms Usa

4 of 4  
Drug NameDexlansoprazole
PubMed HealthDexlansoprazole (By mouth)
Drug ClassesGastric Acid Secretion Inhibitor
Drug LabelThe active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion...
Active IngredientDexlansoprazole
Dosage FormCapsule, extended release
RouteOral
Strength60mg
Market StatusTentative Approval
CompanyPar Pharm

4.2 Drug Indication

Dexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Dexlansoprazole is a proton pump inhibitor (PPI) and is included in the drug class of antisecretory compounds. It blocks the final step of gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the parietal cells on gastric mucosa.


5.2 MeSH Pharmacological Classification

Anti-Ulcer Agents

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)


Proton Pump Inhibitors

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
DEXLANSOPRAZOLE
5.3.2 FDA UNII
UYE4T5I70X
5.3.3 Pharmacological Classes
Proton Pump Inhibitors [MoA]; Proton Pump Inhibitor [EPC]
5.4 ATC Code

A - Alimentary tract and metabolism

A02 - Drugs for acid related disorders

A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

A02BC - Proton pump inhibitors

A02BC06 - Dexlansoprazole


5.5 Absorption, Distribution and Excretion

Absorption

After oral administration, the peak plasma concentration increases approximately dose proportionally. The dual delayed release formulation achieves two plasma concentration peaks, where the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25% of total drug dose) and the second (75% of total drug dose) in the more distal small intestine. The median time (Tmax) to peak plasma concentrations (Cmax) of 30 mg dexlansoprazole was 4 hours and ranged from 1 to 6 hours with the Cmax value of 688 ng/mL. AUC was found to be 3275 (ngh/mL).


Route of Elimination

Dexlansoprazole is cleared from the body by either fecal excretion (50.7%) or renal excretion (47.6%) following oral ingestion, with no unchanged drug detected in the urine.


Volume of Distribution

The apparent volume of distribution after multiple doses in symptomatic GERD patients was 40.3 L.


Clearance

Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/hour, respectively, after five days of 30 or 60 mg once daily administration.


5.6 Metabolism/Metabolites

Dexlansoprazole is extensively metabolized in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.


Lansoprazole has known human metabolites that include 5-Hydroxylansoprazole and Lansoprazole Sulfone.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.


5.8 Mechanism of Action

Dexlansoprazole inhibits the H/K ATPase enzyme, which is involved in the secretion of hydrochloric acid, hydrolyzing ATP and exchanging H+ ions from the cytoplasm for K+ ions in the secretory canaliculus, which results in HCl secretion into the gastric lumen. Dexlansoprazole inhibits this effect of H/K ATPase by demonstrating a high degree of activation in the acidic environment. After passing through the liver and reaching the gastric parietal cells activated by a meal, PPIs undergo protonation in the acidic pH environment, followed by conversion to sulphenamide which represents the active form of the drug. Sulphenamide inhibits the activity of the proton pump and hence the transport of hydrogen ions into the gastric lumen via covalent binding to the SH groups of the cysteine residues of H/K ATPase. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25% of total drug dose) and the second (75% of total drug dose) in the more distal small intestine. Dexlansoprazole reduces both basal and stimulated gastric acid secretion.


DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 30MG

USFDA APPLICATION NUMBER - 22287

read-more

DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 60MG

USFDA APPLICATION NUMBER - 22287

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Controlled & Modified Release

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Co-Processed Excipients

read-more
read-more

Direct Compression

read-more
read-more

Emulsifying Agents

read-more
read-more

Lubricants & Glidants

read-more
read-more

Empty Capsules

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

API Stability Enhancers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Topical

read-more
read-more

Granulation

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Soft Gelatin

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 138530-94-6 / Dexlansoprazole API manufacturers, exporters & distributors?

Dexlansoprazole manufacturers, exporters & distributors 1

26

PharmaCompass offers a list of Dexlansoprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dexlansoprazole manufacturer or Dexlansoprazole supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dexlansoprazole manufacturer or Dexlansoprazole supplier.

PharmaCompass also assists you with knowing the Dexlansoprazole API Price utilized in the formulation of products. Dexlansoprazole API Price is not always fixed or binding as the Dexlansoprazole Price is obtained through a variety of data sources. The Dexlansoprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Dexlansoprazole

Synonyms

(r)-lansoprazole, 138530-94-6, Kapidex, R-(+)-lansoprazole, Dexilant, Dexilant solutab

Cas Number

138530-94-6

Unique Ingredient Identifier (UNII)

UYE4T5I70X

About Dexlansoprazole

The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.

DEXILANT SOLUTAB Manufacturers

A DEXILANT SOLUTAB manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DEXILANT SOLUTAB, including repackagers and relabelers. The FDA regulates DEXILANT SOLUTAB manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DEXILANT SOLUTAB API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of DEXILANT SOLUTAB manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

DEXILANT SOLUTAB Suppliers

A DEXILANT SOLUTAB supplier is an individual or a company that provides DEXILANT SOLUTAB active pharmaceutical ingredient (API) or DEXILANT SOLUTAB finished formulations upon request. The DEXILANT SOLUTAB suppliers may include DEXILANT SOLUTAB API manufacturers, exporters, distributors and traders.

click here to find a list of DEXILANT SOLUTAB suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

DEXILANT SOLUTAB USDMF

A DEXILANT SOLUTAB DMF (Drug Master File) is a document detailing the whole manufacturing process of DEXILANT SOLUTAB active pharmaceutical ingredient (API) in detail. Different forms of DEXILANT SOLUTAB DMFs exist exist since differing nations have different regulations, such as DEXILANT SOLUTAB USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A DEXILANT SOLUTAB DMF submitted to regulatory agencies in the US is known as a USDMF. DEXILANT SOLUTAB USDMF includes data on DEXILANT SOLUTAB's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DEXILANT SOLUTAB USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of DEXILANT SOLUTAB suppliers with USDMF on PharmaCompass.

DEXILANT SOLUTAB KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a DEXILANT SOLUTAB Drug Master File in Korea (DEXILANT SOLUTAB KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DEXILANT SOLUTAB. The MFDS reviews the DEXILANT SOLUTAB KDMF as part of the drug registration process and uses the information provided in the DEXILANT SOLUTAB KDMF to evaluate the safety and efficacy of the drug.

After submitting a DEXILANT SOLUTAB KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DEXILANT SOLUTAB API can apply through the Korea Drug Master File (KDMF).

click here to find a list of DEXILANT SOLUTAB suppliers with KDMF on PharmaCompass.

DEXILANT SOLUTAB WC

A DEXILANT SOLUTAB written confirmation (DEXILANT SOLUTAB WC) is an official document issued by a regulatory agency to a DEXILANT SOLUTAB manufacturer, verifying that the manufacturing facility of a DEXILANT SOLUTAB active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DEXILANT SOLUTAB APIs or DEXILANT SOLUTAB finished pharmaceutical products to another nation, regulatory agencies frequently require a DEXILANT SOLUTAB WC (written confirmation) as part of the regulatory process.

click here to find a list of DEXILANT SOLUTAB suppliers with Written Confirmation (WC) on PharmaCompass.

DEXILANT SOLUTAB NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DEXILANT SOLUTAB as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for DEXILANT SOLUTAB API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture DEXILANT SOLUTAB as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain DEXILANT SOLUTAB and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DEXILANT SOLUTAB NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of DEXILANT SOLUTAB suppliers with NDC on PharmaCompass.

DEXILANT SOLUTAB GMP

DEXILANT SOLUTAB Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of DEXILANT SOLUTAB GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DEXILANT SOLUTAB GMP manufacturer or DEXILANT SOLUTAB GMP API supplier for your needs.

DEXILANT SOLUTAB CoA

A DEXILANT SOLUTAB CoA (Certificate of Analysis) is a formal document that attests to DEXILANT SOLUTAB's compliance with DEXILANT SOLUTAB specifications and serves as a tool for batch-level quality control.

DEXILANT SOLUTAB CoA mostly includes findings from lab analyses of a specific batch. For each DEXILANT SOLUTAB CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

DEXILANT SOLUTAB may be tested according to a variety of international standards, such as European Pharmacopoeia (DEXILANT SOLUTAB EP), DEXILANT SOLUTAB JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DEXILANT SOLUTAB USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty